Health Care/Hospital
Xinhua Silk Road: BGI Genomics' star COVID-testing mobile lab product exhibited at China Pavilion of Expo 2020 Dubai
BEIJING, Jan. 17, 2022 /PRNewswire/ -- Models of BGI Genomics' Huo-Yan Air Laboratory, a star nucleic acid-testing mobile lab product of the Chinese giant, were displayed at the China Pavilion of Expo 2020 Dubai duringJanuary 11-13. Compared with regular COVID-testing labs, Huo-Yan Air Labs are ...
2022-01-17 10:22
1710
CStone announces the clinical data from registrational study of Sugemalimab in stage III non-small cell lung cancer published in The Lancet Oncology
SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the registrational clinical...
2022-01-15 08:35
5109
CStone announces the registrational clinical study results of sugemalimab in stage IV non-small cell lung cancer published in The Lancet Oncology
SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that results of the GEMSTONE-302...
2022-01-15 08:31
4613
French Consul General in Guangzhou led a delegation to visit Biosyngen in China-Singapore Guangzhou Knowledge City
GUANGZHOU, ChinaJan. 15, 2022 /PRNewswire/ -- On the afternoon of January 14th, Mr. Sylvain FOURRIERE, Consul General ofFrance in Guangzhou, and officers from consulates general of 9 countries includingBritain, Canada and Switzerland visited China-Singapore Guangzhou Knowledge City andSingapore -...
2022-01-15 08:00
4986
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
Results from ongoing testing and monitoring of COVID-19 variants shows the rapid microfluidic test detects Omicron at a comparable sensitivity to other variants LONDON, Jan. 14, 2022 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced tha...
2022-01-14 19:18
2690
Crunchfish Gesture Interaction introduction - Deeply intuitive gestures
STOCKHOLM, Jan. 14, 2022 /PRNewswire/ -- Crunchfish develops AI technology for gesture interaction with exceptional performance, optimized for augmented and virtual reality (AR/VR), automotive and the next generation digital interfaces. An introduction to gesture Interaction was the topic of the ...
2022-01-14 19:17
2507
Leapstack Raised Nearly 150 Million Yuan in Series C Round Financing, Catalyzing Transformation of Intelligent Risk Control in Healthcare Insurance
SHANGHAI, Jan. 14, 2022 /PRNewswire/ -- Recently, Shanghai Leapstack Technology Co., Ltd. (hereinafter referred to as Leapstack), an insurtech company, announced that it had raised a Series C round of150 million yuan. This round of fundraising was led by Legend Capital, followed by Peakview Capit...
2022-01-14 13:00
3940
EW Nutrition showcases innovative solutions at International Dairy Week 2022
SINGAPORE, Jan. 14, 2022 /PRNewswire/ -- EW Nutrition will participate in Australia's International Dairy Week (IDW) in Tatura, Victoria, from January 16 to 20, 2022. Visitors will learn about innovative solutions for ruminant nutrition. Located at Site 37, EW Nutrition also invites attendees to ...
2022-01-14 09:00
1973
Everest Medicines Enters into a Global Licensing Agreement to Develop and Commercialize Singapore's Experimental Drug Development Centre's 3CL Protease Inhibitors as Potentially Best-in-Class COVID-19 Oral Antiviral Treatments Worldwide
SHANGHAI, Jan. 14, 2022 /PRNewswire/ -- Everest Medicines
2022-01-14 08:00
4399
Dr. Luciana Young Named Vice Chair of Inteleos Board of Directors
Pediatric cardiologist, researcher, and professor extends service, gains new responsibility ROCKVILLE, Md., Jan. 13, 2022 /PRNewswire/ -- Inteleos™, a non-profit global healthcare certification organization, today named pediatric cardiologist Dr. Luciana Young, MD, FASE, FAHA, FACC, as vice chair...
2022-01-13 22:48
2456
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne
HANGZHOU and SHAOXING, China, Jan. 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC40 for moderate to severe acne. ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme whic...
2022-01-13 17:30
3229
Apex Medical Rebrands to Wellell, redefining core values
NEW TAIPEI CITY, Taiwan, Jan. 13, 2022 /PRNewswire/ -- Apex Medical has placed utmost importance on the value of human life, while providing agile services and high-quality medical devices since 1990. The rebranding in 2022 affirms the determination to establish a global foothold and further evol...
2022-01-13 16:00
2178
Accuredit Therapeutics and N1 Life Form a Joint Venture Named 'Napoltec', Dedicated to the Development of Therapeutic Drug Delivery Systems and Pressing Ahead Clinical Translation
SUZHOU, China, Jan. 13, 2022 /PRNewswire/ -- Accuredit Therapeutics (Suzhou) Co., Ltd. (hereinafter referred to as Accuredit), an emerging company based on new generations of safe and highly targeted gene editing therapies, and N1 Life, a biotech company focused on developing cutting-edge drug de...
2022-01-13 13:33
2640
NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression
SINGAPORE, Jan. 13, 2022 /PRNewswire/ -- Moleac is pleased to announce the release of the ATHENE study results, published in the Journal of the American Medical Director Association (JAMDA)1. Alzheimer's Disease (AD) and other dementias cause a heavy economic and public healthcare burden worldw...
2022-01-13 12:32
2251
Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046
* Interim analysis expected in the second quarter of 2022 SUZHOU, China, Jan. 13, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical study of KN026 (HER2 bispecific antibody) combined with KN046 (PD-L1/CTLA-4 bispecific antibody) (KN026-203) has su...
2022-01-13 10:46
3028
CStone announces phase 2 GEMSTONE-201 trial met primary endpoint of objective response rate (ORR) in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL)
* Sugemalimab has the potential to become the world's first immunotherapy to be approved for patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) * The National Medical Products Administration (NMPA) of China has granted the Breakthrough Therapy Designati...
2022-01-13 08:05
5805
Seegene Unveils Blueprint for the Future of Molecular Diagnostics, Including Open Development Platform at the 40th Annual J.P. Morgan Healthcare Conference
SEOUL, South Korea, Jan. 13, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics (MDx) company, today, unveiled its blueprint for the future during a presentation at the 40th annual J.P. Morgan Healthcare virtual Conference. Dr.Jong-Yoon Chun, CEO of Seegene...
2022-01-13 04:00
2638
Ascend to build HMD plant in China's Jiangsu province
HOUSTON, Jan. 12, 2022 /PRNewswire/ -- Ascend Performance Materials announced today it signed an investment agreement to construct a new hexamethylene diamine and specialty chemicals plant in Lianyungang,China in the Xuwei New Area Park. The new plant will be Ascend's first chemical production fa...
2022-01-12 23:00
3211
Largest Global Health Network Havas Health & You Certified As "Great Place to Work"
NEW YORK, Jan. 12, 2022 /PRNewswire/ -- On the heels of a year that continued to cement health as more important than ever, the largest global health network Havas Health & You today announced that it has been named a "Great Place to Work", with employees reporting more than 20% higher satisfacti...
2022-01-12 22:31
1804
Dr. Michael Lilly elected to Chair of Inteleos Board of Directors
ROCKVILLE, Md., Jan. 12, 2022 /PRNewswire/ -- Inteleos™, a non-profit healthcare certification organization, today announced Dr.Michael Lilly, MD, RVT, RPVI,has been named as Chairperson of its Board of Directors. A long-time volunteer with Inteleos and its ARDMS Council, Dr. Lilly brings extensi...
2022-01-12 22:03
1739
Week's Top Stories
Most Reposted
Another 'Reason to Travel': Agoda and Singapore Tourism Board Renew Partnership to Boost Travel to Singapore
[Picked up by 350 media titles]
2024-06-19 11:00
MIFB 2024 ENLISTS F&B EXPERTS TO SPEAK ON THE LATEST IN INDUSTRY TRENDS AND THE FUTURE OF FOOD
[Picked up by 335 media titles]
2024-06-20 16:24
k-ID Closes $45 Million Series A from Andreessen Horowitz and Lightspeed Venture Partners to Set a New Global Benchmark for Age-appropriate Gaming Experiences
[Picked up by 318 media titles]
2024-06-25 21:00
New Study Finds Cybersecurity as Top Concern Among Automotive Manufacturers
[Picked up by 317 media titles]
2024-06-19 08:05THEIR ROYAL HIGHNESSES THE DUKE AND DUCHESS OF EDINBURGH CELEBRATE THE GRAND OPENING OF THE PENINSULA LONDON, BELGRAVIA
[Picked up by 313 media titles]
2024-06-19 11:38
Most Read
Another 'Reason to Travel': Agoda and Singapore Tourism Board Renew Partnership to Boost Travel to Singapore
2024-06-19 11:00
15653
MIFB 2024 ENLISTS F&B EXPERTS TO SPEAK ON THE LATEST IN INDUSTRY TRENDS AND THE FUTURE OF FOOD
2024-06-20 16:24
13314
New Study Finds Cybersecurity as Top Concern Among Automotive Manufacturers
2024-06-19 08:05
9440
